目的探讨药物联合人际心理治疗难治性抑郁症患者的临床效果。方法将难治性抑郁症患者100例按随机数字表法随机分为对照组和研究组,每组50例。对照组患者口服草酸艾司西酞普兰+奥氮平治疗,研究组患者在对照组治疗的基础上给予人际心理治疗,两组患者均治疗12周。采用汉密尔顿抑郁量表(AHMD)和汉密尔顿焦虑量表(HAMA)评价两组患者的疗效,采用健康状况调查问卷(SF-36)评价两组患者的生活质量,采用不良反应量表(TESS)评价治疗的安全性。结果两组患者HAMD、HAMA总分随着治疗时间的延续呈下降趋势,治疗后两组患者在不同时间点上的总分比较差异有统计学意义(P<0.01);治疗后两组患者总分比较差异有统计学意义(P<0.01)。治疗12周末,研究组患者治疗总有效率(90.0%)显著高于对照组(72.0%),研究组患者临床疗效优于对照组(P<0.05)。治疗后,两组患者各SF-36因子评分均显著高于治疗前(P<0.01);研究组患者各因子评分显著高于对照组(P<0.05或0.01)。两组患者不良反应比较差异无统计学意义(P>0.05)。研究组和对照组患者的TESS量表评分比较差异无统计学意义(P>0.05)。结论药物联合人际心理治疗难治性抑郁症患者能显著提高抗抑郁治疗的临床效果,有效改善患者生活质量。
ObjectiveTo evaluate the efficacy of medicine combined with interpersonal psychotherapy (IPT) in treatment of patients with treatment-resistant depression (TRD). MethodsA total of 100 patients with TRD were randomly divided into study group and control group,with 50 cases in each group. The control group was treated with escitalopram oxalate and olanzapine, while the study group received IPT on the basis of control group, the course of treatment of both groups was 12weeks. Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA)were used to evaluate the efficacy, the short form-36 health survey (SF-36) was used to evaluate the quality of life, and the side effects was assessed with treatment emergent symptoms scale(TESS). ResultsThe HAMD score and HAMA score in both groups decreased along with treatment, that was a statistical differences in HAMD score and HAMA score between two groups after treatment (P<0.01), and that was a statistical differences in HAMD score and HAMA score between two groups at difference treatment point (P<0.01).After 12 weeks of treatment, the total effective rate of treatment in the study group ( 90.0%) was significantly higher than that in the control group (72.0%), and the clinical efficacy in the study group was significantly superior to that in the control group (p<0.05). After treatment, SF-36 scores in both groups were significantly higher than those before treatment (P<0.01), and SF-36 scores in the study group were significantly higher than those in the control group (P<0.05 or P<0.01).That was no significant difference of adverse reaction and TESS scores were found between the two groups (P>0.05). ConclusionsMedicine combined with interpersonal psychotherapy in treatment of patients with treatment-resistant depression (TRD) can improve the efficacy and enhance the quality of life.